血脂异常
医学
脂肪肝
高甘油三酯血症
胰岛素抵抗
内科学
疾病
脂质代谢
糖尿病
2型糖尿病
代谢综合征
生物信息学
肥胖
内分泌学
胆固醇
生物
甘油三酯
作者
Audrey Deprince,Joel T. Haas,Bart Staels
标识
DOI:10.1016/j.molmet.2020.101092
摘要
Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI